2. Academic Validation
  3. Discovery and Optimization of First-in-Class Furopyrimidine-Based Inhibitors of Henipaviruses

Discovery and Optimization of First-in-Class Furopyrimidine-Based Inhibitors of Henipaviruses

  • J Med Chem. 2026 Jan 22;69(2):1264-1285. doi: 10.1021/acs.jmedchem.5c02646.
Irina N Gaisina 1 2 3,  Malaika D Argade 1 2,  Ryan Bott 4,  Sean P Bradley 1 2,  Łukasz Tomorowicz 1 2,  Mario Alvarez 2,  Jazmin M Galván Achi 4,  Robert W Cross 5,  Viktoriya Borisevich 5,  Rachel O'Toole 5,  Moushimi Amaya 6,  Christian A Zielinski 1 2,  Arsen M Gaisin 1 2,  Dejan Nikolic 1 2,  Paul R Carlier 1 2,  Manu Anantpadma 7,  Terry W Moore 2,  Christopher C Broder 6,  Thomas W Geisbert 5,  Norton P Peet 3,  Lijun Rong 3 4
Affiliations

Affiliations

  • 1 UICentre: Drug Discovery, University of Illinois Chicago, Chicago, Illinois 60612, United States.
  • 2 Department of Pharmaceutical Sciences, University of Illinois Chicago, Chicago, Illinois 60612, United States.
  • 3 Chicago BioSolutions Inc., Chicago, Illinois 60612, United States.
  • 4 Department of Microbiology and Immunology, University of Illinois Chicago, Chicago, Illinois 60612, United States.
  • 5 Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas 77555, United States.
  • 6 Department of Microbiology and Immunology, Uniformed Services University, Bethesda, Maryland 20814, United States.
  • 7 The Integrated Research Facility, National Institute of Allergy and Infectious Diseases, Frederick, Maryland 21702, United States.
PMID: 41492812 DOI: 10.1021/acs.jmedchem.5c02646
Abstract

Henipaviruses such as Nipah (NiV) and Hendra (HeV) are zoonotic pathogens that cause severe and often fatal respiratory illness and encephalitis in both Animals and humans. These viruses exhibit high transmissibility and pandemic potential, a situation made worse by the absence of appropriate pharmaceutical countermeasures. To address this deficit, we conducted a hit-to-lead optimization campaign based on hit 1 identified through high-throughput screening against recombinant Cedar virus (rCedV), a nonpathogenic surrogate for NiV and HeV. This effort yielded a focused library of analogs that were initially screened against rCedV, with promising candidates subsequently validated against authentic NiV and HeV. Among these, analog 46 demonstrated superior in vitro metabolic stability and pharmacokinetic properties relative to hit 1 and is now positioned for in vivo efficacy evaluation. Concurrently, the mechanism of action of these first-in-class furopyrimidine-based Antiviral agents was probed through time-of-addition assays, escape mutation analysis, and preliminary in silico modeling.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z